Search results
MacroGenics to Participate in Upcoming Investor Conferences
Morningstar· 4 days agoROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal ...
GSK to divest remaining 4.2% stake in Haleon
Pharmaceutical Technology via Yahoo Finance· 4 hours agoThe agreement comprises an upfront payment of $1bn and $400m in regulatory milestone payments. Through the deal, GSK will gain access to AIO-001, a...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 4 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 4 days agoAlso, Lyvgen’s monoclonal antibody (mAb) dalnicastobart has seen its transition prospects increase...
Uniquity Bio launches to focus on immunology and inflammation
Pharmaceutical Technology via Yahoo Finance· 1 day agoA monoclonal antibody, solrikitug targets thymic stromal lymphopoietin. It will treat critical...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 7 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 6.3% in April
ETF DAILY NEWS· 9 hours agoAdagene Inc. (NASDAQ:ADAG – Get Free Report) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 15,100 shares, an increase ...
Sanofi to Spend $1.08 Billion to Boost Drug Production in France
Morningstar· 4 days agoSanofi will spend more than 1 billion euros ($1.08 billion) on ramping up production capability in France. The French pharmaceutical company said Monday that the bulk of the investment will ...
Critics Say FDA's Use of Surrogate Markers Falling Short
Medscape· 8 hours agoAs the FDA's use of surrogate endpoints in the drug approval process is increasing, researchers are concerned important post-approval or validation studies are lacking.
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Morningstar· 7 days agoTORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...
